DUBLIN--(BUSINESS WIRE)--The "Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Cancer Vaccine Partnering 2012-2018 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2012.
The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.
The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
One of the key highlights of the report is that over 250 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2012.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Cancer Vaccine dealmaking
Chapter 3 - Leading Cancer Vaccine deals
Chapter 4 - Most active Cancer Vaccine dealmakers
Chapter 5 - Cancer Vaccine contracts dealmaking directory
Chapter 6 - Cancer Vaccine dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/kvtdzk/global_cancer?w=4